Articles On Cann Group (ASX:CAN)

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

ASX ends day on new record high at 8597 points 10 of 11 sectors higher with broad strength across market Materials leads gains, up 1.38pc   ASX almost breaks through 8600-point ceiling The ASX 200 had one of its best trading days in month...

Doctor visits dipped in April, reversing a recovery trend Mayne Pharma threatens to go legal in takeover dispute … but peace erupts at Cann Group with settlement of legal spat   We’re either a healthy lot, rely on Dr Google or simply can’...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights Surge in prescriptions for medical cannabis is accelerating domestic production and diversification Regulatory advancements enabling broader patient access and product innovation Australia emerging as a regional h...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Australia’s S&P/ASX 200 rallies 3.62% in April, showing resilience to global geopolitical and economic uncertainty Ten out of 11 sectors post gains in April, led by communications up 6.47% followed by a 6.37% comeback from tech DY6 Met...

ASX falls 0.82pc, led down by energy and healthcare stocks Gold rises to all-time high at US$3,215 per ounce Oil falls to levels not seen since April 2020, at height of Covid-19 pandemic Despite pulling back on Tuesday, gold prices have h...

Highlights: ASX lifts sharply with all sectors closing higher, rebounding from prior session declines Nikkei records strong movement as markets respond to tariff rhetoric Resource and tech firms lead gains, while a few small...

ASX rallies 2.27% after shedding 4% yesterday Nikkei225 soars almost 6%, recovering from Monday’s losses Trade war threatens to escalate as China calls tariff escalations ‘a mistake’.   The ASX posted a strong gain to rise 2.27% today, re...

Companies including Cochlear and Telix affirm that tariffs are likely to be a ‘Y2K’ non-event Bell Potter says Trajan shares are worth double their current price Plucky Biotron lives another day after passing the hat   On the evening of D...

Trump’s tariffs shake markets, billions wiped off ASX Gold shines as trade war fears spark safe haven rush China, EU prep retaliation as global recession fears rise   Trump’s tariffs have hit markets hard, wiping almost $30 billion off th...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

The initial buzz surrounding ASX cannabis stocks saw a lot of early investors reap a lot of early profits, while many latecomers lost their shirts. The party started when Canada and the United States moved to legalise not just medicinal can...

A few years ago the market was abuzz with excitement over ASX cannabis shares or pot stocks. Since then, the effects have worn off and this side of the market has been getting very little attention. That was until today when two ASX cannabi...

When we were kids eyeing an unobtainable treat or the not-so-imminent arrival of Santa, Mum used to tell us to be patient. Patience, indeed, is a virtue and an admirably quality to exhibit throughout one’s adult life. But there are circumst...

Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell   When Rene...

ASX slipped after early gains, then finished strongly  Energy sector helped offset losses; Quickstep, Sigma Healthcare turned heads Wall Street rallied to record highs after Trump’s win   The ASX swung from gains, to losses at lunchtime,...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

EBOS Group affirms current-year earnings expectations Cannabis stocks report mixed quarterly revenue and earnings trends Atomo Diagnostics gets federal backing for syphilis home test   As the competition regulator mulls the proposed $8.8...

  ASX closes  higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans   The ASX closed 0.13% higher on Wednesday, thanks...

Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow   It’s not th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Renewed optimism lifted the S&P/ASX 200 by 3% in September, closing at a record 8,239.20 points S&P Dow Jones Indices said small cap companies outperformed in September, with the materials sector rebounding 13%  Mithril Silver and...

ASX dips as miners lead selloff as Chinese markets close for holidays Sigma Healthcare soars 22pc after merger update Qantas tumbles 4pc as Qatar eyes Virgin Australia stake   The ASX dipped  from its record high as miners led the sellof...

ASX rises modestly with mining stocks leading gains Fortescue surges nearly 5pc as iron ore prices climb on fresh China stimulus Odessa soars on news of a $1,1m placement to secure exploration at its Lyndon uranium project   The ASX scal...

  ASX rises modestly with mining stocks leading gains Fortescue surges nearly 5pc as iron ore prices climb Star Entertainment plunges over 40pc after trading halt lifted   The ASX rose modestly by 0.1% on Friday, buoyed by a surge in min...

ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts   The ASX200 hit yet another record high today, boosted by the first inte...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

As Cann Group (ASX: CAN) looks to finally reap the fruits of its capital-intensive $115 million Mildura production and manufacturing facility, the fast-growing medicinal cannabis company has been pulling out all stops to shore up finances a...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Albanese govt announces the Future Made in Australia Act Why supporting Australian Made is a win-win game Stockhead reached out to Australian Made CEO, Ben Lazzaro   The ambitiously named Future Made in Australia Act was launched a couple...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Cann Group (ASX: CAN) CEO Peter Koetsier has tendered his resignation just 14 months after assuming leadership of the medicinal cannabis company, which is growing sales at a fast clip but remains burdened by the debts incurred as a result o...

Content Director Patrick Poke of Betashares explores the risks associated with impulsively reacting to investment trends fuelled by media hype, and explain why prudent asset selection, diversification, and maintaining a composed approach ar...

Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month   It hasn’t been a stellar month for global cannabis stocks, with the index falling by...